S. Yao

ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers

S. Sakamuri, Feng Tian, S. Biroc, 2020, Molecular Cancer Therapeutics.

Nonclinical Development of Next-generation Site-specific HER2-targeting Antibody–drug Conjugate (ARX788) for Breast Cancer Treatment

Feng Tian, Yi Gu, Yanping Ji, 2020, Molecular Cancer Therapeutics.

Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpresing solid tumors: Results from two phase 1 clinical trials.

G. T. Budd, J. O’Shaughnessy, G. Budd, 2021, Journal of Clinical Oncology.

Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432

Y. Jiang, Y. Ba, R. Xu, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.